Physician profile
Bryan Vinik
NPI 1649384157
$13,024.87
in general payments reported to CMS, 2019-2025
43 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,804 · 2020: $1,011 · 2021: $2,844 · 2022: $1,395 · 2023: $1,629 · 2024: $1,212 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.23 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,074.31 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $1,342.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $946.76 | 2019-2025 | |
| Novo Nordisk INC | $860.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $612.83 | 2019-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $501.53 | 2019-2025 | Korlym |
| Insulet Corporation | $441.43 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $416.67 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $266.36 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $255.25 | 2019-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.44 | 2019-2024 | Cycloset |
| Xeris Pharmaceuticals, INC. | $229.44 | 2020-2025 | Gvoke Hypopen |
| Mannkind Corporation | $204.28 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.88 | 2019-2024 | Jardiance |
| Recordati_rare_diseases_inc. | $158.19 | 2021-2025 | Isturisa, Signifor Lar |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130.09 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $114.93 | 2019-2021 | |
| Horizon Therapeutics Plc | $110.45 | 2019-2022 | |
| Lifescan, INC. | $94.57 | 2020-2022 | |
| Becton, Dickinson and Company | $70.06 | 2019-2021 | |
| Ibsa Pharma INC. | $59.67 | 2021-2022 | |
| Radius Health, INC. | $59.45 | 2019-2022 | |
| Nevro Corp. | $58.01 | 2023 | Senza |
| Avvisto Therapeutics, LLC | $49.37 | 2024-2025 | Cycloset |
| Madrigal Pharmaceuticals | $49.12 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $46.69 | 2024 | Tlando |
| Valeritas, INC. | $46.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.69 | 2019-2020 | |
| Eusa Pharma (US) LLC | $41.77 | 2022 | |
| Dexcom, INC. | $40.63 | 2023-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $36.40 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $27.16 | 2019 | |
| Sandoz INC. | $23.13 | 2025 | |
| Pfizer INC. | $21.93 | 2023 | |
| Kyowa Kirin, INC. | $20.31 | 2024 | Crysvita |
| Grt US Holding, INC. | $19.72 | 2021 | |
| Alvogen INC | $19.48 | 2023 | Teriparatide |
| Esperion Therapeutics, INC. | $18.75 | 2024 | Nexletol |
| Medtronic, INC. | $17.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.50 | 2019 | |
| Abbott Laboratories | $16.53 | 2021 | |
| Senseonics, Incorporated | $13.00 | 2019 | |
| Linus Health, INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Vinik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.